Core Viewpoint - Microelectrophysiology (688351.SH) reported a total operating revenue of 465 million yuan for the year 2025, representing a year-on-year growth of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Financial Performance - The company achieved a net profit of 23.66 million yuan after deducting non-recurring gains and losses, a significant increase from 5.08 million yuan in 2024 [1] International Expansion - The company's overseas revenue grew by over 40% year-on-year, accounting for more than 30% of total revenue, indicating the effective implementation of its internationalization strategy [1] - High-end pressure monitoring radiofrequency ablation catheters have been commercialized in over 20 countries [1] - The cryoablation system received EU certification and is being commercially applied in countries such as Germany, Turkey, and Greece, with positive clinical feedback [1] Brand and Market Development - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution through high-quality live surgeries and seminars, gaining widespread attention and recognition in the industry [1] - Future strategies include continuous product innovation, strengthening brand development, and expanding channel networks to enhance competitiveness in overseas markets [1]

微电生理发布业绩快报，2025年度实现营业总收入4.65亿元，同比增长12.43%；净利润5115.17万元， 同比下降1.76%。报告期内，公司海外布局持续深化，业务发展取得显著成果。2025年度，公司海外收 入同比增长超过40%，总收入占比已超过30%，有力验证了国际化战略的有效推进，凸显出公司在技 术、产品与服务方面的综合竞争优势。 ...

每经头条（nbdtoutiao）——10倍价差刷屏！"外国人来华就医"火了，三位亲历者这样说⋯⋯ （记者 曾健辉） 每经AI快讯，微电生理2月10日晚间发布公告称，公司限售股份约3.46亿股将于2026年3月2日解禁并上 市流通，占公司总股本比例为73.47%。 ...

重要内容提示： 证券代码：688351 证券简称：微电生理 公告编号：2026-004 上海微创电生理医疗科技股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 345,740,119股。 本次股票上市流通总数为345,740,119股。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会出具的《关于同意上海微创电生理医疗科技股 份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕1587 号），公司获 准向社会公众公开发行人民币普通股（A 股）70,600,000 股，并于 2022 年 8 月 31 日在上海证券交易所科创板上市。首次公开发行后公司总股本为 470,600,000 股，其中有限售条件流通股为 408,130,829 股，无限售条件流通股为 62,469,171 股。 本次上市流通的限售股为公司首次公开发行前部分限售股，涉及的限售股股 东数量为 4 名，对应股份数量为 345, ...

核查意见 根据中国证券监督管理委员会出具的《关于同意上海微创电生理医疗科技股 份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕1587 号），公 司获准向社会公众公开发行人民币普通股（A 股）70,600,000 股，并于 2022 年 8 月 31 日在上海证券交易所科创板上市。首次公开发行后公司总股本为 470,600,000 股，其中有限售条件流通股为 408,130,829 股，无限售条件流通股为 62,469,171 股。 本次上市流通的限售股为公司首次公开发行限售股份，涉及的限售股股东数 量为 4 名，系嘉兴华杰一号股权投资合伙企业（有限合伙）（以下简称"嘉兴华 杰"）、天津爱德博瑞企业管理合伙企业（有限合伙）（以下简称"爱德博瑞"）、 微创投资控股有限公司（以下简称"微创投资"）、上海生晖企业管理咨询中心 （有限合伙）（以下简称"上海生晖"），对应股份数量为 345,740,119 股，占 公司总股本的 73.47%。上述股东原股份限售期为自公司首次公开发行上市之日 起 36 个月，因相关股东履行承诺自动延长 6 个月锁定期，合计 42 个月。2025 年 9 月 12 日，公司披露 ...

近日，微电生理发布公告称，公司的磁导航消融导管及星型高密度标测导管于近日获得了欧盟医疗器械 法规（MDR）认证证书。 此次认证将助力公司进入欧洲市场，依托高附加值产品进一步扩大海外收入规模，并完善海外"标测 +消融"技术矩阵。 ...

Industry and Company Overview - The medical consumables sector showed a slight increase, with the sector index closing at 6067.61 points, up by 0.35% [2] - The performance of leading companies in the medical consumables sector included Maipu Medical (+8.5%), Hualan Biological (+7.5%), and Zhend Medical (+6.7%), while underperformers included Microelectrophysiology (-2.9%) and Daobo Medical (-3%) [2] Market Valuation Metrics - As of February 6, the medical consumables sector had a PE ratio of 36.1X, down by 0.23X from the previous week, with a one-year high of 40.1X and a low of 28.88X; the PB ratio was 2.61X, with a one-year high of 2.92X and a low of 2.13X [4] Recent Developments - Microelectrophysiology's product, a disposable intracardiac ultrasound imaging catheter, has been approved for market release, enhancing its core product offerings in cardiac intervention and filling a gap in integrated ultrasound imaging and electrophysiological mapping solutions [5] Investment Recommendations - There is a high certainty of continued performance recovery for some high-value consumable companies, driven by recent approvals of innovative products and overseas business development, which are expected to create new growth points outside of centralized procurement [6] - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the orthopedic implants, cardiovascular intervention devices, and neurosurgical implants sectors, as well as those with advantages in rehabilitation and chronic disease management [6][7]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

证券代码：688351 证券简称：微电生理 公告编号：2026-003 上海微创电生理医疗科技股份有限公司 关于部分产品获得欧盟 MDR 认证 的自愿性披露公告 证书编号 产品名称 预期用途 M.2026.MDR.1096 FireMagic™ Magbot™消融导管 适用于基于导管的心脏电生理标测； 与兼容的射频发生器配合使用时，还 适用于治疗心房颤动和室上性心动 过速；与兼容 RMT（磁导航技术相 关）的三维电生理导航系统（3D EP Navigation System）配合使用时，可 提供定位信息。 EasyStars™高密度 标测导管 适用于对心脏内的心脏结构进行多 电极电生理标测；与兼容的三维电生 理 导 航 系 统 （ 3D EP Navigation System）配合使用时，可提供定位信 息。 一、欧盟MDR认证证书的具体情况 公司进入欧洲市场，依托高附加值产品进一步扩大海外收入规模，还完善了公司 海外"标测+消融"技术矩阵，与现有三维标测系统形成完整解决方案，强化了 全能量消融技术壁垒，同时凭借精准、高效、安全的产品特性提升客户粘性、夯 实全球化品牌认知，为产品快速出海奠定了坚实基础。 上述 ...

公司磁导航消融导管及星型高密度标测导管获欧盟MDR认证，不仅助力公司进入欧洲市场，依托高附 加值产品进一步扩大海外收入规模，还完善了公司海外"标测+消融"技术矩阵，与现有三维标测系统形 成完整解决方案，强化了全能量消融技术壁垒，同时凭借精准、高效、安全的产品特性提升客户粘性、 夯实全球化品牌认知，为产品快速出海奠定了坚实基础。 格隆汇2月9日丨微电生理(688351.SH)公布，公司磁导航消融导管及星型高密度标测导管于近日获得了 欧盟医疗器械法规(The Medical DeviceRegulations (EU) 2017/745，以下简称"MDR")认证证书。 ...